Functional differences between low- and highaffinity CD8+ T cells in the tumor environment

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1239-1247

  Bos, Rinke ^a   Marquardt, Kristi L ^a   Cheung, Jocelyn ^a   Sherman, Linda A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CD4 help; CD8+ T cells; T cell function; TCR affinity; Tumor environment

Indexed keywords

BIM PROTEIN; GAMMA INTERFERON; GRANZYME; GRANZYME B; INTERLEUKIN 2; KI 67 ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL CLONE; CELL COUNT; CELL DIFFERENTIATION; CELL INFILTRATION; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REJECTION; UPREGULATION;

EID: 84879619273     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21285     Document Type: Article

References (41)

1. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24:571-606; PMID:16551260; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115601.
2. Sprent J, Kishimoto H. The thymus and negative selection. Immunol Rev 2002; 185:126-35; PMID:12190927; http://dx.doi.org/10.1034/j.1600-065X.2002.18512.x.
3. Miller JF, Kurts C, Allison J, Kosaka H, Carbone F, Heath WR. Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens. Immunol Rev 1998; 165:267-77; PMID:9850866; http://dx.doi.org/10.1111/j.1600-065X.1998.tb01244.x.
4. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000; 13:829-40; PMID:11163198; http://dx.doi.org/10.1016/S1074-7613(00)00080-7.
5. Nugent CT, Morgan DJ, Biggs JA, Ko A, Pilip IM, Pamer EG, et al. Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. J Immunol 2000; 164:191-200; PMID:10605011.
6. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003; 21:807-39; PMID:12615893; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141135.
7. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437:141-6; PMID:16136144; http://dx.doi.org/10.1038/nature03954.
8. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239:27-44; PMID:21198663; http://dx.doi.org/10.1111/j.1600-065X.2010.00979.x.
9. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100.
10. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322.
11. Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122-31; PMID:18292535.
12. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ. Genetically modulating T-cell function to target cancer. Semin Cancer Biol 2012; 22:14-22; PMID:22210183; http://dx.doi.org/10.1016/j.semcancer.2011.12.006.
13. Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 2007; 110:3564-72; PMID:17660381; http://dx.doi.org/10.1182/blood-2007-02-075010.
14. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535-46; PMID:19451549; http://dx.doi.org/10.1182/blood-2009-03-211714.
15. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/science.1129003.
16. Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 2005; 174:2563-72; PMID:15728462.
17. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001; 61:5850-6; PMID:11479225.
18. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996; 93:4102-7; PMID:8633023; http://dx.doi.org/10.1073/pnas.93.9.4102.
19. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678-89; PMID:17717539; http://dx.doi.org/10.1038/nri2156.
20. Marelli-Berg FM, Cannella L, Dazzi F, Mirenda V. The highway code of T cell trafficking. J Pathol 2008; 214:179-89; PMID:18161751; http://dx.doi.org/10.1002/path.2269.
21. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature 2009; 458:211-4; PMID:19182777; http://dx.doi.org/10.1038/nature07657.
22. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989-94; PMID:9916724.
23. Bullock TN, Mullins DW, Colella TA, Engelhard VH. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol 2001; 167:5824-31; PMID:11698456.
24. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulinspecific CD8+ T cells. J Exp Med 2003; 197:643-56; PMID:12615905; http://dx.doi.org/10.1084/jem.20021378.
25. Savinov AY, Wong FS, Chervonsky AV. IFN-gamma affects homing of diabetogenic T cells. J Immunol 2001; 167:6637-43; PMID:11714835.
26. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196:999-1005; PMID:12370261; http://dx.doi.org/10.1084/jem.20020666.
27. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000; 290:1354-8; PMID:11082062; http://dx.doi.org/10.1126/science.290.5495.1354.
28. Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000; 192:117-22; PMID:10880532; http://dx.doi.org/10.1084/jem.192.1.117.
29. D'Souza WN, Lefrançois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol 2003; 171:5727-35; PMID:14634080.
30. Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol 2011; 12:908-13; PMID:21804558; http://dx.doi.org/10.1038/ni.2079.
31. Verdeil G, Marquardt K, Surh CD, Sherman LA. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A 2008; 105:16683-8; PMID:18936481; http://dx.doi.org/10.1073/pnas.0805054105.
32. Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J Immunol 2006; 176:4834-42; PMID:16585578.
33. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107:7875-80; PMID:20385810; http://dx.doi.org/10.1073/pnas.1003345107.
34. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems. J Clin Invest 2007; 117:3383-92; PMID:17932562; http://dx.doi.org/10.1172/JCI31184.
35. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620.
36. Sheu BC, Chiou SH, Lin HH, Chow SN, Huang SC, Ho HN, et al. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res 2005; 65:2921-9; PMID:15805295; http://dx.doi.org/10.1158/0008-5472.CAN-04-2108.
37. Kessels HW, Schepers K, van den Boom MD, Topham DJ, Schumacher TN. Generation of T cell help through a MHC class I-restricted TCR. J Immunol 2006; 177:976-82; PMID:16818753.
38. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A 2005; 102:7934-9; PMID:15908507; http://dx.doi.org/10.1073/pnas.0500357102.
39. Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, et al. Cooperation of human tumorreactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005; 22:117-29; PMID:15664164; http://dx.doi.org/10.1016/j.immuni.2004.12.005.
40. Lyman MA, Aung S, Biggs JA, Sherman LA. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 2004; 172:6558-67; PMID:15153470.
41. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000 132:365-86; PMID:10547847.